Targeting RTK Signaling Pathways in Cancer
AbstractThe RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of proliferation, differentiation and survival. The induction of these pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding. In cancer, constitutive and aberrant activations of components of those pathways result in increased proliferation, survival and metastasis. For instance, mutations affecting RTKs, Ras, B-Raf, PI3K and AKT are common in perpetuating the malignancy of several types of cancers and from different tissue origins. Therefore, these signaling pathways became prime targets for cancer therapy. This review aims to provide an overview about the most frequently encountered mutations, the pathogenesis that results from such mutations and the known therapeutic strategies developed to counteract their aberrant functions. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Regad, T. Targeting RTK Signaling Pathways in Cancer. Cancers 2015, 7, 1758-1784.
Regad T. Targeting RTK Signaling Pathways in Cancer. Cancers. 2015; 7(3):1758-1784.Chicago/Turabian Style
Regad, Tarik. 2015. "Targeting RTK Signaling Pathways in Cancer." Cancers 7, no. 3: 1758-1784.